Antibiotics

A recent review article on the status of vaccines in development for healthcare associated infections (HAIs) provides both an in-depth discussion of their urgent need, as well as their potential for success.

Researchers from the department of pathology at the Beth Israel Deaconess Medical Center in Boston developed and validated a high-throughput screen (HTS) that could detect antimicrobial agents with the ability to restore carbapenem susceptibility to resistant strains, as well as those that target CRE directly.

For patients who suffer from certain uncomplicated infections such as, sinusitis, bronchitis, and uncomplicated urinary tract infections, the health risks associated with fluoroquinolone far outweigh the benefits.

Older antibiotic agents show decreased potency due to overuse and the subsequent emergence of drug-resistant bacteria. This antimicrobial resistance has been predicted to have enormous consequences for human health, necessitating the development of new agents in the ongoing war between humans and the germs that attack us.

Antibiotic-resistant pathogens continue to make the management of some bacterial infections a significant clinical challenge.

Adding to the troubling data worldwide on antibiotic resistance, researchers have found that even trace concentrations of antibiotics, such as those found in sewage, are sufficient for bacteria to maintain resistance to most broad-spectrum agents.

Two new inhibitory compounds—named KKL-10 and KKL-40—could hold the key to preventing the proliferation of the highly virulent bacterium Francisella tularensis, according to a recent study.

On April 18, 2016, the director-general of the World Health Organization, Margaret Chan, OBE, JP, discussed antimicrobial resistance at a United Nations briefing in New York.

On March 8, 2016, researchers at the Ulsan National Institute of Science and Technology reported the development of an antibacterial fabric that inhibits the growth of bacteria, including antibiotic-resistant bacteria.

Dorothy McCoy, PharmD, explains what patients in the hospital should do if they have concerns about their medications.

US hospitals have made significant reductions in the incidence of hospital-acquired infections (HAIs) over the past decade, a new report from the Centers for Disease Control and Prevention (CDC) has revealed.

The Centers for Disease Control and Prevention believes far too many Americans are exposed to "dangerous, drug-resistant bacteria" in hospitals and other healthcare settings.

Jason C. Gallagher, PharmD explains the most important thing healthcare practitioners should keep in mind about antimicrobial stewardship.

Researchers have discovered a new class of chemical compounds that work to inhibit biofilm formation, thereby identifying a potential new therapeutic target for the treatment of infections caused by Acinetobacter baumannii.

A recent article endeavors to draw new-- and perhaps increased-- attention to the issue of neurologic side effects associated with antibiotic use in hospitalized patients.

Jason C. Gallagher, PharmD explains what healthcare providers can do to help address antimicrobial resistance.

The antibacterial drug Avycaz (ceftazidime-avibactam) was given priority review by the Food and Drug Administration (FDA) since new safety data has been discovered.

A new trial conducted in England has discovered a cost-effective way to reduce the overprescribing of antibiotics by general practitioners (GPs).

Dr. Jason C. Gallagher, PharmD, Clinical Professor at the Temple University School of Pharmacy describes the difference between antimicrobial and antibiotic resistance.

Jason C. Gallagher, PharmD, explains what healthcare providers can do to help address antibiotic resistance.

After swabbing 20 beards, more than 100 bacteria growths were identified.

There appears to be a positive correlation between higher antibiotic use and the development of type 2 diabetes, according to a study published in The Journal of Clinical Endocrinology & Metabolism.